Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × Uterine Cervical Neoplasms × Vinorelbine × Clear all

Phase

Status

Completed 5 Withdrawn 1 Recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 10 Hodgkin Disease 3 Carcinoma, Non-Small-Cell Lung 3 Rhabdomyosarcoma 2 Recurrence 2 Advanced Breast Cancer 2 Uterine Cervical Neoplasms 1 Triple Negative Breast Neoplasms 1 Neoplasms 1 Neoplasm Metastasis 1 NSCLC 1 Lung Neoplasms 1 HER2-positive Advanced Breast Cancer 1 HER2-negative Breast Cancer 1 Fludzoparib" and Anti-angiogenic 1 Carcinoma, Squamous Cell 1 Carcinoma, Large Cell 1 Adenocarcinoma 1

Interventions

pembrolizumab 20 Cisplatin 17 Carboplatin 12 Radiotherapy 9 Paclitaxel 9 Bevacizumab 9 Drug Therapy 7 Colposcopy 7 Brachytherapy 7 Blood Specimen Collection 6 Specimen Handling 5 Human Papillomavirus DNA Tests 5 camrelizumab 4 Nivolumab 4 Mass Screening 4 Injections 4 Gemcitabine 4 Chemotherapy, Adjuvant 4 Chemoradiotherapy 4 Biopsy 4 toripalimab 3 lenvatinib 3 Taxes 3 Surveys and Questionnaires 3 Radiation 3 Magnetic Resonance Imaging 3 Fulvestrant 3 Cyclophosphamide 3 zimberelimab 2 spartalizumab 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06459180 2026-03-13

TroFuse-020

Merck Sharp & Dohme LLC

Phase 3 Recruiting

Uterine Cervical Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡